Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.
J Ethnopharmacol. 2019 Sep 15;241:112032. doi: 10.1016/j.jep.2019.112032. Epub 2019 Jun 18.
Traditional herbal medicine has been taken as a new and effective approach to treat many chronic diseases. Xiexin Tang (XXT), a compound recipe composed of Dahuang (Rheum palmatum L.), Huangqin (Scutellaria baicalensis Georgi) and Huanglian (Coptis chinensis Franch.), has been reported to have hypoglycemic and hypolipidemic effects, but its mechanism remains unclear. Our previous study found that Xiexin Tang markedly ameliorated the composition of the gut microbiota, especially for some short chain fatty acids (SCFAs) producing bacteria, and then notably increased SCFAs production. However, the mechanism of XXT on the fermentation of gut bacteria and further improvement of obesity is not yet clear.
This study aimed to unravel the molecular mechanism of XXT on the amelioration of obesity.
Here, high-fat diet-induced obese rat model was established to investigate the intervention efficacy following oral administration of XXT. Additionally, the expressions of key enzymes of gut microbe-derived SCFAs biosynthesis and key targets in the signaling pathway of energy metabolism were investigated by ELISA and qPCR analysis.
Results showed that XXT could notably correct lipid metabolism disorders, alleviate systematic inflammation, improve insulin sensitivity and reduce fat accumulation. Additionally, XXT could increase gut microbiota-derived SCFAs-producing capacity by enhancing mRNA levels and activities of SCFA-synthetic key enzymes such as acetate kinase (ACK), methylmalonyl-CoA decarboxylase (MMD), butyryl-CoA: acetate CoA transferase (BUT) and butyrate kinase (BUK), which markedly decreased the adenosine triphosphate (ATP) contents, elevated adenosine diphosphate (ADP) and adenosine monophosphate (AMP) levels and further lowered the energy charge (EC) in obese rats via activating peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/uncoupling protein-2 (UCP-2) signaling pathway. What's more, XXT could notably ameliorate dyslipidemia via increasing the gene expression of 5'-AMP-activated protein kinase (AMPK) and blocking mammalian target of rapamycin (mTOR) signaling pathway.
Taken together, our data provided a novel insight into the role of XXT in losing weight from energy metabolism regulation, which unraveled the molecular mechanism of XXT on the alleviation of dyslipidemia and fat heterotopic accumulation. The study provided useful information for XXT in clinical application to treat obesity.
传统草药已被视为治疗许多慢性疾病的新方法和有效途径。泻心汤(XXT)是一种由大黄(Rheum palmatum L.)、黄芩(Scutellaria baicalensis Georgi)和黄连(Coptis chinensis Franch.)组成的复方方剂,据报道具有降血糖和降血脂作用,但作用机制尚不清楚。我们之前的研究发现,泻心汤能显著改善肠道微生物群的组成,特别是一些短链脂肪酸(SCFA)产生菌,从而显著增加 SCFA 的产生。然而,XXT 对肠道细菌发酵和进一步改善肥胖的作用机制尚不清楚。
本研究旨在揭示 XXT 改善肥胖的分子机制。
在这里,建立高脂肪饮食诱导的肥胖大鼠模型,以研究口服 XXT 后的干预效果。此外,通过 ELISA 和 qPCR 分析,研究了肠道微生物衍生 SCFA 生物合成的关键酶和能量代谢信号通路中的关键靶点的表达。
结果表明,XXT 能显著纠正脂质代谢紊乱,减轻全身炎症,提高胰岛素敏感性,减少脂肪堆积。此外,XXT 能通过增强 SCFA 合成关键酶如乙酰激酶(ACK)、甲基丙二酰辅酶 A 脱羧酶(MMD)、丁酰辅酶 A:乙酰辅酶 A 转移酶(BUT)和丁酰激酶(BUK)的 mRNA 水平和活性,增加肠道微生物衍生的 SCFA 产生能力,从而显著降低肥胖大鼠的三磷酸腺苷(ATP)含量,升高二磷酸腺苷(ADP)和一磷酸腺苷(AMP)水平,并通过激活过氧化物酶体增殖物激活受体γ共激活因子 1-α(PGC-1α)/解偶联蛋白 2(UCP-2)信号通路进一步降低能量电荷(EC)。更重要的是,XXT 通过增加 5'-AMP 激活蛋白激酶(AMPK)的基因表达并阻断哺乳动物雷帕霉素靶蛋白(mTOR)信号通路,显著改善血脂异常。
综上所述,我们的数据为 XXT 通过能量代谢调节减肥提供了新的见解,揭示了 XXT 缓解血脂异常和脂肪异位积累的分子机制。该研究为 XXT 治疗肥胖症的临床应用提供了有用的信息。